Key facts
- This page summarizes Krishna Yeshwant's Form 4 filing for EQRx, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Nov 2023, 16:12.
Krishna Yeshwant - 09 Nov 2023 Form 4 Insider Report for EQRx, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 09 Nov 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Nov 2023, 16:12:09 UTC
- Prior SEC filing
- 20 Jun 2023
- Next SEC filing
- 05 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Collins, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Krishna Yeshwant filed Form 4 for EQRx, Inc. on 09 Nov 2023.
Change
- Previous filing in this sequence was filed on 20 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EQRX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -101,010
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Nov 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 101,010
- Exercise price
- $4.95
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Krishna Yeshwant is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.
Footnote F2
Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.
Footnote F3
At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).